Navigation Links
Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
Date:9/4/2007

- Results Presented at 12th World Conference on Lung Cancer in Seoul -

SOUTH SAN FRANCISCO, Calif., Sept. 4 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that updated results of its Phase 2 clinical trial of picoplatin confirm and extend the previously announced interim data analysis, which demonstrated a survival benefit in patients with recurrent small cell lung cancer (SCLC) who have relapsed within six months of first-line therapy. The company also for the first time announced the median one-year survival rate of 17.6 percent in the Phase 2 population of mostly platinum-refractory and -resistant patients studied in this trial. Picoplatin, the Company's lead product candidate, is currently being evaluated in the pivotal Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial in SCLC, which is being conducted under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA). The SPEAR trial is being conducted in platinum-refractory, -resistant, and -sensitive SCLC patients who have failed or relapsed from initial therapy within six months of initial treatment and is comparing picoplatin treatment with best supportive care to best supportive care alone. The median overall survival is approximately 17 to 22 weeks for patients with recurrent SCLC who are treated with existing second-line chemotherapies, according to the 2007 National Comprehensive Cancer Network practice guidelines.

"These updated Phase 2 data are consistent with earlier studies of picoplatin in this difficult-to-treat patient population and compare favorably with the median survival for the entire populatio
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
2. Poniard Pharmaceuticals Announces Clinical Data from Picoplatin Phase 2 Small Cell Lung Cancer Trial To Be Presented at American Society of Clinical Oncology Annual Meeting
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 18, 2014  RESMED INC. (NYSE: ... quarter of fiscal year 2015 results on Thursday, January 22, ... press release with ResMed,s results will be issued after 1:00 ... webcast to discuss operating results and future outlook. ... US Pacific Time and the live webcast of the call ...
(Date:12/19/2014)... INDIANAPOLIS and LYON, France ... (NYSE: LLY ) and Adocia (Euronext Paris: ... focused on developing an ultra-rapid insulin, known as BioChaperone ... type 2 diabetes. BioChaperone Lispro relies on Adocia,s proprietary ... Lilly and Adocia will develop BioChaperone Lispro ...
(Date:12/17/2014)... Revenue and earnings above the previous ... development In the past 2013/14 fiscal year (ended ... to EUR 4.287 billion (last year: EUR 4.190 billion) despite ... EUR 360 million. "Overall, 2013/14 was a successful fiscal year ... President and CEO of Carl Zeiss AG. "Thanks to our ...
Breaking Medicine Technology:ResMed To Announce Second Quarter 2015 Results 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3ZEISS Asserts its Position in Difficult Environment 2
... to Initiate Phase 2b in Second Quarter of 2008 ... - Conference Call Tomorrow at 8:00 a.m. Eastern Time ... Inc.,(Nasdaq: RDEA ) today announced positive preliminary results ... novel,investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), in,patients with human ...
... to Develop Disease Treatments for Diabetic Kidney Disease and ... Retinopathy, Each Multi-Billion-Dollar Drug Markets, JENKINTOWN, Pa., March ... new class of compounds that inhibit the,production of RAGE, ... that a RAGE inhibitor would be an important,addition to ...
Cached Medicine Technology:Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load 2Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load 3Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load 4Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor 2
(Date:12/19/2014)... Dotinga HealthDay Reporter ... including ibuprofen, might slightly reduce your risk of developing ... of ibuprofen (Advil, Motrin) and naproxen (Aleve) appear to ... 15 percent, the researchers concluded after reviewing nine prior ... sun exposure. These painkillers "have potential ...
(Date:12/17/2014)... 17, 2014 While countless companies tempt patients ... realize the potential dangers of their purchase. Not only is ... a qualified doctor, but patients who buy hCG online are ... there is actually no real hCG present. Illegal internet hCG ... are no safety standards and may contain unknown fillers that ...
(Date:12/17/2014)... December 17, 2014 HeartMath® Inc., ... on stress, heart rate variability (HRV), heart coherence ... its extensive HRV databases and algorithms to chipset ... will enable HeartMath’s partners to offer its HRV ... research, as well as its normative HRV databases ...
(Date:12/17/2014)... 2014 Now in its second year, ... of the best in senior living and home care ... to communities and agencies that have received outstanding online ... the nearly 100,000 providers currently listed on SeniorAdvisor.com, only ... SeniorAdvisor.com Best of 2015 Awards are located all over ...
(Date:12/17/2014)... News) -- Expectant parents should leave prenatal picture-taking to ... Use of ultrasound imaging and heartbeat monitors to ... the agency warns. "Although there is a ... imaging and heartbeat monitors, prudent use of these devices ... an FDA biomedical engineer, said in an agency news ...
Breaking Medicine News(10 mins):Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 3Health News:Diet Doc Reveals the Real Dangers for Those who Buy hCG Online 2Health News:Diet Doc Reveals the Real Dangers for Those who Buy hCG Online 3Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 3Health News:The Inn at Willow Falls - Crest Hill, IL Wins 2015 Best of Assisted Living Award from SeniorAdvisor.com 2Health News:The Inn at Willow Falls - Crest Hill, IL Wins 2015 Best of Assisted Living Award from SeniorAdvisor.com 3Health News:FDA Warns Against Fetal 'Keepsake' Videos 2
... March 6 Pregis Corporation, a leading,international ... and specialty packaging solutions, will conduct an ... quarter and full year results on,Thursday, March ... a.m. CT). The call can be,accessed through ...
... 6 Champions,Biotechnology, Inc. (OTC Bulletin Board: CSBR), a ... results.,Full details of the Company,s financial results are available ... For the three months ended January 31, 2008 the ... of $0.02 compared to a net loss,of $37,198 and ...
... EBITDA up 33%, TORONTO, March 6 /PRNewswire-FirstCall/ - ... products and services to the global life,sciences markets, today ... reported net revenues of $296 million, net income of ... $0.14.,Adjusted EBITDA rose to $40 million, up from $30 ...
... Essilor International, the world leader in,ophthalmic optical products, today announced its audited financial results,for the year ended December 31, 2007., ... 2007 2006(2) ... 2,908.1 2,690.0 ... 482.6 + 9.3%, As a % of revenue ...
... The following is a,statement in response to Patrick Swayze ... CEO of the Pancreatic Cancer,Action Network, the only national ... support, community outreach and,advocacy for a cure., "We ... with,pancreatic cancer and our thoughts go out to him ...
... Letter asks Senate Budget Leaders to Reject Oxygen ... Reform Much More Difficult,to Achieve, Letter Draws ... March 5 The Council for Quality,Respiratory Care ... home oxygen,therapy providers and manufacturers who provide care ...
Cached Medicine News:Health News:Champions Biotechnology, Inc. Reports Two Cents per Share Earnings for Three Quarters Ended January 31, 2008 2Health News:Champions Biotechnology, Inc. Reports Two Cents per Share Earnings for Three Quarters Ended January 31, 2008 3Health News:MDS Reports First Quarter 2008 Results 2Health News:MDS Reports First Quarter 2008 Results 3Health News:MDS Reports First Quarter 2008 Results 4Health News:MDS Reports First Quarter 2008 Results 5Health News:MDS Reports First Quarter 2008 Results 6Health News:MDS Reports First Quarter 2008 Results 7Health News:MDS Reports First Quarter 2008 Results 8Health News:MDS Reports First Quarter 2008 Results 9Health News:MDS Reports First Quarter 2008 Results 10Health News:MDS Reports First Quarter 2008 Results 11Health News:MDS Reports First Quarter 2008 Results 12Health News:MDS Reports First Quarter 2008 Results 13Health News:MDS Reports First Quarter 2008 Results 14Health News:MDS Reports First Quarter 2008 Results 15Health News:MDS Reports First Quarter 2008 Results 16Health News:MDS Reports First Quarter 2008 Results 17Health News:MDS Reports First Quarter 2008 Results 18Health News:MDS Reports First Quarter 2008 Results 19Health News:MDS Reports First Quarter 2008 Results 20Health News:MDS Reports First Quarter 2008 Results 21Health News:MDS Reports First Quarter 2008 Results 22Health News:MDS Reports First Quarter 2008 Results 23Health News:MDS Reports First Quarter 2008 Results 24Health News:MDS Reports First Quarter 2008 Results 25Health News:MDS Reports First Quarter 2008 Results 26Health News:MDS Reports First Quarter 2008 Results 27Health News:MDS Reports First Quarter 2008 Results 28Health News:MDS Reports First Quarter 2008 Results 29Health News:MDS Reports First Quarter 2008 Results 30Health News:MDS Reports First Quarter 2008 Results 31Health News:MDS Reports First Quarter 2008 Results 32Health News:MDS Reports First Quarter 2008 Results 33Health News:Essilor : 2007 Results 2
... for Cardiology is the first digital solution ... modalities both within and outside cardiology. From ... the archival solutions, Agfas combined expertise in ... and their customers to work the way ...
Full Digital Ultrasound System...
... the latest technologies to help expand your ... These advancements increase system utility and provide ... visualization of even the smallest details. And ... information delivery and expedite a higher quality ...
This catheter is intended for ultrasound examination of coronary intravascular pathology ONLY. Intravascular ultrasound imaging is indicated in patients who are candidates for transluminal coronary i...
Medicine Products: